Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma

TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction.

The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at ERS International Congress 2021, 5-8 September 2021.

Questions

1. How much of a problem is OCS dependency in severe asthma? (0:12)
2. Could you tell us a little about the PONENTE study and its findings to date? (0:45)
3. What are the implications of these findings for the severe asthma treatment landscape? (1:58)
4. What will be the next steps in your research? (2:46)

Disclosures: Andrew Menzies-Gow discloses attending advisory boards for Astra Zeneca, Sanofi, Novartis and Glaxo SmithKline; Receiving speaker fees from AZ, Novartis, Teva and Sanofi; and has participated in research with AZ.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of ERS 2021 (Virtual).